Signal Transduction and Targeted Therapy (Dec 2021)

Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice

  • Zhenfei Bi,
  • Weiqi Hong,
  • Haiying Que,
  • Cai He,
  • Wenyan Ren,
  • Jingyun Yang,
  • Tianqi Lu,
  • Li Chen,
  • Shuaiyao Lu,
  • Xiaozhong Peng,
  • Xiawei Wei

DOI
https://doi.org/10.1038/s41392-021-00851-6
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 12

Abstract

Read online

Abstract The development of animal models for COVID-19 is essential for basic research and drug/vaccine screening. Previously reported COVID-19 animal models need to be established under a high biosafety level condition for the utilization of live SARS-CoV-2, which greatly limits its application in routine research. Here, we generate a mouse model of COVID-19 under a general laboratory condition that captures multiple characteristics of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) observed in humans. Briefly, human ACE2-transgenic (hACE2) mice were intratracheally instilled with the formaldehyde-inactivated SARS-CoV-2, resulting in a rapid weight loss and detrimental changes in lung structure and function. The pulmonary pathologic changes were characterized by diffuse alveolar damage with pulmonary consolidation, hemorrhage, necrotic debris, and hyaline membrane formation. The production of fatal cytokines (IL-1β, TNF-α, and IL-6) and the infiltration of activated neutrophils, inflammatory monocyte-macrophages, and T cells in the lung were also determined, suggesting the activation of an adaptive immune response. Therapeutic strategies, such as dexamethasone or passive antibody therapy, could effectively ameliorate the disease progression in this model. Therefore, the established mouse model for SARS-CoV-2-induced ARDS in the current study may provide a robust tool for researchers in the standard open laboratory to investigate the pathological mechanisms or develop new therapeutic strategies for COVID-19 and ARDS.